European Association for the Study of the Liver

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Retrieved on: 
Wednesday, November 8, 2023
Radiation therapy, Standard of care, DOTATATE, NYSE, Washington University in St. Louis, CATX, European Association of Nuclear Medicine, Mallinckrodt Institute of Radiology, PRRT, Glomus tumor, Tissue, Washington University School of Medicine, SSTR2, European Association for the Study of the Liver, NETS, TAT, Safety, Fast track (FDA), Therapy, Patient, Pharmaceutical industry, Radiology

The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).

Key Points: 
  • The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).
  • “We are proud of our team’s commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors,” said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics.
  • “The development of Perspective’s [212Pb]VMT-α-NET targeted alpha particle therapy is an important next step in the evolution of treatments for SSTR2-expressing tumors.
  • We are excited to participate in the trial.”
    “We are excited about our collaboration with investigators from top-tier research centers who are evaluating [212Pb]VMT-α-NET in patients with intractable SSTR2-expressing neuroendocrine tumors,” said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, Survival, Action, Biomarker, Neuro, MOS, DMG, SNO, Conference, CNS, Central nervous system, ONC201, Annual general meeting, ACTION, European Association for the Study of the Liver, Pakistan Society of Neuro-Oncology, Cancer Discovery (journal), Patient, Human, Completeness, Pharmaceutical industry

DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.

Key Points: 
  • ET Today –
    DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an operational update.
  • Chimerix reported a net loss of $24.0 million, or $0.27 per basic and diluted share, for the third quarter of 2023.
  • Research and development expenses increased to $17.4 million for the third quarter of 2023, compared to $15.3 million for the same period in 2022.
  • Chimerix will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a business update today at 8:30 a.m.

CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023

Retrieved on: 
Monday, October 23, 2023
Ethnographic Museum of the University of Zurich, Patient, American College, IL-31, Itch, UDCA, The Duke of Edinburgh's International Award - Canada, Hope, Pathology, Conditional sentence, NRS, Liver, ALP, American College of Gastroenterology, HIV disease progression rates, PBC, Ursodeoxycholic acid, Risk, European Association for the Study of the Liver, Research and development, Cholestatic pruritus, Alkaline phosphatase, Primary biliary cholangitis, University, EASL, Cholestasis, Atopic dermatitis, Therapy, Doctor of Philosophy, Pharmaceutical industry, Research, MD

VANCOUVER, British Columbia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced today the presentation of findings from its post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC), showing baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31. The presentation, named the recipient of this year’s International Award by the American College of Gastroenterology, will be presented by Professor Andreas E. Kremer, MD, Ph.D., MHBA, a leading authority in cholestatic pruritus from the University of Zurich. Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.

Key Points: 
  • Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.
  • The data were previously presented at the European Association for the Study of the Liver (EASL)’s The International Liver Congress™ 2023 in Vienna, Austria.
  • “These results offer a glimmer of hope in that they link IL-31 levels in patients with PBC to itch.
  • Elevated risk due to ELF was identified in 43.2% of patients who currently meet guidelines for second-line treatment vs. 27.2% within patient groups not recommended for second-line treatment.

Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183, Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Plaque Psoriasis at EADV Congress 2023

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Congress, European Association for the Study of the Liver, PASI, Meiji, BID, Outline, Safety, Psoriasis, Psoriasis Area and Severity Index, PDE4, QD, Traffic barrier, Patient, Pharmaceutical industry, Dermatology, Venereology

In total, 132 patients were randomly assigned to ME3183 (n=26, 26, 26, and 27, respectively) or placebo (n=27).

Key Points: 
  • In total, 132 patients were randomly assigned to ME3183 (n=26, 26, 26, and 27, respectively) or placebo (n=27).
  • Mean Psoriasis Area and Severity Index (PASI) score at baseline was 15.9–17.6 and 16.8 in the ME3183 and placebo groups, respectively.
  • In conclusion, ME3183 administered orally was effective in the treatment of plaque psoriasis and had an acceptable safety profile.
  • Meiji strives to provide efficacious and safe treatment for unmet medical needs, such as psoriasis and other autoimmune diseases.

Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Pain, European Association for the Study of the Liver, TRIBUTE, Trial of the century, University Medical Center, Tildrakizumab, BME, Venereology, Safety, ALM, Congress, University Medical Center Schleswig Holstein, Itch, Quality of life (healthcare), Almirall, Pros, RCT, Grammatical mood, Skin, Patient, Quality of life, Medical device, Medical imaging, Psoriasis, Dermatology

Tildrakizumab significantly improved relatives’ wellbeing after 28 weeks.2

Key Points: 
  • Tildrakizumab significantly improved relatives’ wellbeing after 28 weeks.2
    During the congress held in Berlin from October 11th to 14th, Almirall presented 12 posters highlighting new data on tildrakizumab in patients with moderate-to-severe plaque psoriasis.
  • Additionally, the symposium titled “New Landmark on Psoriasis treatment: the POSITIVE study”, chaired by Prof. Dr. Matthias Augustin and Prof. Dr. Ulrich Mrowietz, will explore the impact of tildrakizumab on physical, social and mental wellbeing in psoriasis.
  • Understanding the broader implications of psoriasis is a significant advance in our field and underlines the importance of a holistic approach to its treatment.
  • These data demonstrate the consolidated effectiveness and safety of tildrakizumab in treating plaque psoriasis and patients’ overall wellbeing.

New Physician Guidelines Recommend Contrast Enhanced Ultrasound to Diagnose Certain Liver Cancers

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Hospitals, Health Technology, General Health, Biotechnology, CME, ACR, CT, Radiation, University, GE HealthCare, Internal medicine, Hepatocellular carcinoma, Liver disease, Neoplasm, Thomas Jefferson University, CEUS, Society, Agent handling, United States of Europe, University of California, San Diego Performance-Based Skills Assessment, Approximation error, MR, Brain, Kidney, Radiology, Black, AASLD, Google Images, Patient, Risk, Physician, Treatment, American Indians, Liver cancer, ICUS, University of Bologna, Diagnosis, European Association for the Study of the Liver, American College, FDA, White, HCC, UCAS, Medical imaging, Medical device, Liver, Biology, Medicine

New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.

Key Points: 
  • New physician guidelines now recommend use of contrast-enhanced ultrasound (CEUS) to diagnose hepatocellular carcinoma (HCC), the most common primary liver cancer.
  • The new guidelines recommend CEUS for diagnosing HCC when MR and CT are inconclusive, unavailable or contraindicated.
  • CEUS uses FDA-approved “microbubble” ultrasound contrast agents (UCAs) that are administered intravenously during an ultrasound scan.
  • UCAs are manufactured and sold in the US and elsewhere by Bracco, Lantheus and GE Healthcare.

Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, September 25, 2023
Astrocytoma, Poster, European Association for the Study of the Liver, Radiation, RT, Therapy, GBM, SAN, Neuro-Oncology (journal), Safety, Annual general meeting, Pharmaceutical industry

SAN DIEGO, Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam.

Key Points: 
  • SAN DIEGO, Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, today announced the presentation of compelling patient case studies in a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting in Rotterdam.
  • In the first case, a 32-year-old woman with grade four GBM (MGMT-unmethylated) received conventional radiotherapy with concurrent chemotherapy with VAL-083 followed by adjuvant VAL-083 for a total of 13 cycles of VAL-083.
  • The patient was tumor-free and has survived more than four years as of the last follow-up in March 2023.
  • The patient was re-treated with VAL-083 and was stable as of the last follow-up in March 2023.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023
Pheochromocytoma, DOTATATE, NETS, MBBS, EANM, TAT, Thyroid cancer, Quality of life, DNB, Nuclear medicine, Paraganglioma, PET-CT, Șaeș, Non-small-cell lung cancer, MDS, Hair, Targeted molecular therapy for neuroblastoma, CATX, Patient, Standard of care, Syndrome, Molina Healthcare, FMRI, European Association for the Study of the Liver, Therapy, NYSE, PRRT, Meningioma, Safety, Fatigue, Pharmaceutical industry

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, September 11, 2023
Survival rate, Glomus tumor, NETS, Radiation, Index, Probability, Metastasis, EANM, SCID, Neoplasm, Survival, WWIC, Toxicity, Research, Nuclear medicine, Neuroendocrine cell, Congress, Korea Military Academy, Korea, CATX, WMIC, Mouse, MTD, European Association for the Study of the Liver, Therapy, NYSE, Human, Pharmaceutical industry, Medical imaging

SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the World Molecular Imaging Congress (WMIC) 2023, held on September 5-9, 2023, in Prague, Czech Republic, and the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from September 9-13, 2023.

Key Points: 
  • Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs).
  • The study was carried out by Dr. Dongyoul Lee, an assistant professor at the Korea Military Academy.
  • The dose depositions in tumor and normal organs were estimated based on 203Pb biodistribution data.
  • In addition, tumor progression, survival rates, and body weight changes over a 120-day period were assessed, and favorable radiochemical characteristics were observed.

Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023

Retrieved on: 
Thursday, September 7, 2023
Research, Medical Devices, Clinical Trials, Health Technology, Other Health, Biotechnology, General Health, Health, Science, Other Science, Proton, Fatty liver disease, EASL, NASH, Fibrosis, NDRA, Poster, European Association for the Study of the Liver, Magnetic resonance imaging, Medical imaging, Czechoslovakia, Liver

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a clinical abstract titled “Thermoacoustic assessment of fatty liver disease - a clinical feasibility study” for presentation at the Steatotic Liver Disease Summit™ 2023 hosted by the European Association for the Study of the Liver (EASL), taking place September 21-23 in Prague, Czechoslovakia.
  • “This poster presentation is focused on a comparison of TAEUS estimates of liver fat fraction to the established clinical gold standard of Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF).
  • We are delighted that ENDRA's clinical abstract was accepted by EASL for its annual summit focused on steatotic liver disease, which is the target of ENDRA's first TAEUS application.
  • The study data add to ENDRA's growing clinical evidence and illustrate TAEUS' potential to assess fatty liver disease, non-invasively, at the point of care, in populations that include large subjects, and those with NASH or fibrosis,” stated Michael Thornton, Chief Technology Officer of ENDRA.